Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**PentaLyte** is BioTime's proprietary intravenous colloid plasma-volume expander consisting of 6% pentastarch in a balanced lactated electrolyte solution. The formulation contains hydroxyethyl starch as the principal oncotic volume-expanding component, with electrolytes, glucose, and lactate buffer. It was developed for treatment of hypovolemia, particularly where relatively faster elimination of the starch component is desired. In a rabbit aortic occlusion-reperfusion model, PentaLyte resuscitation reduced hepatoenteric reperfusion injury and associated lung injury relative to lactated Ringer's resuscitation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/876343/000095013404020044/f04328exv99w1.htm))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PentaLyte.